Vinorelbine
- Generic Name
- Vinorelbine
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting .
A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug .
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate .
For the treatment of recurrent or metastatic squamous cell head and neck cancer .
For the treatment of recurrent ovarian cancer .
For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy .
For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus .
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-03-24
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00005865
- Locations
- 🇺🇸
NorthBay Healthcare System, Fairfield, California, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-03-17
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Amgen
- Registration Number
- NCT00006215
- Locations
- 🇺🇸
Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group, Memphis, Tennessee, United States
🇺🇸Texas Cancer Care, Fort Worth, Texas, United States
🇺🇸Gould Medical Group, Modesto, California, United States
Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2013-03-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 3300
- Registration Number
- NCT00002823
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇸🇮University of Ljubljana, Ljubljana, Slovenia
Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Japan Multinational Trial Organization
- Registration Number
- NCT00079287
- Locations
- 🇯🇵
Nagoya University Hospital, Aichi, Japan
🇯🇵Asahikawa Medical College, Asahikawa, Japan
🇯🇵National Hospital Organization - Ehime National Hospital, Ehime, Japan
Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1800
- Registration Number
- NCT00003240
- Locations
- 🇬🇧
Middlesex Hospital- Meyerstein Institute, London, England, United Kingdom
Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00017459
- Locations
- 🇺🇸
University of Florida Health Science Center - Jacksonville, Jacksonville, Florida, United States
🇺🇸Los Angeles County Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸John Wayne Cancer Institute, Santa Monica, California, United States
Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-03-14
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 13
- Registration Number
- NCT00014430
- Locations
- 🇺🇸
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
Vinorelbine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- First Posted Date
- 2004-02-03
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 59
- Registration Number
- NCT00008333
- Locations
- 🇺🇸
Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸CCOP - Geisinger Clinic and Medical Center, Danville, Pennsylvania, United States
🇺🇸CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma
- Conditions
- Malignant Mesothelioma
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 840
- Registration Number
- NCT00075699
- Locations
- 🇬🇧
Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom
🇬🇧Leeds General Infirmary at Leeds Teaching Hospital NHS Trust, Leeds, England, United Kingdom
🇬🇧Saint Bartholomew's Hospital, London, England, United Kingdom
Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-01-12
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00075673
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.